Insider buying last 90 days
No open-market insider purchases were filed for EWTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Edgewise Therapeutics moved this week on a cluster of catalysts. Shares jumped 12% on a report of takeover interest, with an "uncooked" alert suggesting the company hired advisers for a sales process involving two European pharmas and one US-listed company. Separately, the company announced a productive End-of-Phase 2 meeting with the FDA for EDG-7500 in hypertrophic cardiomyopathy, with the STRATUS-HCM Phase 3 protocol submitted and featuring tolerability-based dose escalation. Third-quarter results showed EPS of $9.65 against an estimate of ($0.53), with net income of $1.17 billion driven largely by the $1.396 billion upfront sale of the sevasemten program to Servier, a drug that had missed trial endpoints. Management also confirmed plans for Phase 2 EQUINOX-HFpEF dosing and upcoming investor conference appearances.
EWTX closed at $48.74, up 8.2% on the day, sitting above both its 50-day ($40.97) and 200-day ($36.65) averages, with the shorter average above the longer one. The GekkoIndex reading of 39.5 places the stock in the Distribution zone, down 22.4 points over five sessions. Price sits 14.7% above the $42.48 Gekko Fair Value estimate.
Over the next 20 trading days, the next earnings report is not due until 25 February 2027, 107 days out. Options activity shows 1 unusual signal in the last 30 days, with call premium of $1,112,230 against no put premium. Seasonally, the stock has averaged a 4.3% move over this stretch across 5 years, rising in 3 of them. Analyst consensus stands at 9 buy and 2 hold ratings among 11 firms, with a $54 consensus target.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Edgewise Therapeutics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $45.93 is above the 50-day ($41.33) and 200-day ($37.01) averages, and the 50-day is above the 200-day.
See the chart49.9, Neutral
Reading 49.9 is in the Neutral zone.
See the GekkoIndex6.1% above
Price is 6.1% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings−5.5% on average
From this point in the calendar, the next 20 trading days averaged −5.5% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Edgewise Therapeutics closed at $45.93 on Nov 13, 2026, +117.0% over the past year, inside a 52-week range of $19.76 to $48.78.
Use the left and right arrow keys to read daily values.
Put EWTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Edgewise Therapeutics works on small-molecule drugs aimed at muscle and skeletal diseases that stem from genetic causes. Its furthest-along candidate, EDG-5506, is a pill designed to address the root genetic mechanisms behind dystrophinopathies such as Duchenne and Becker muscular dystrophy, and it has already completed Phase 1 testing. This program is the company's most recognized effort to date.
Alongside EDG-5506, Edgewise is advancing additional precision medicine candidates intended to act on specific muscle proteins, with the goal of treating other muscle disorders that have a defined genetic basis. The company's work centers on this pipeline of investigational compounds rather than on marketed products, reflecting a drug-development approach built around genetically targeted conditions.
Edgewise Therapeutics was founded in 2017 and is based in Boulder, Colorado. Its shares trade on the NASDAQ under the ticker EWTX.
Edgewise Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.9, in the Neutral zone, up 1.8 points over five sessions.
Up 1.8 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 14 | −0.2% | +16.1% |
| Accumulation | 215 | +1.9% | +2.4% |
| Neutral (current zone) | 428 | +1.1% | +5.1% |
| Distribution | 33 | −3.8% | −2.4% |
| Selling | 12 | +21.3% | +19.8% |
Average EWTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Edgewise Therapeutics trades 6.1% above Gekko Fair Value of $43.29, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Edgewise Therapeutics shares are worth, recalculated every trading day.
$43.29
Gekko Fair Value, Nov 14, 2026
6.1% Overvalued
At the end of Aug 2026 the price was 13.5% below the estimate.
No open-market insider purchases were filed for Edgewise Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for EWTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in EWTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Nov 6, $1.11M in unusual premium.
0of the funds Gekko tracks hold EWTX.
Edgewise Therapeutics reports on Feb 25, 2027 (102 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 25, 2027
102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $9.65 est −$0.53 | — est $119.2M | +3.2% |
| Aug 6, 2026 | −$0.53 est −$0.48 | — | −3.3% |
| May 7, 2026 | −$0.46 est −$0.48 | — | −4.5% |
| Feb 26, 2026 | −$0.47 est −$0.43 | — | +1.1% |
| Nov 6, 2025 | −$0.39 est −$0.40 | — | −1.2% |
| Aug 7, 2025 | −$0.34 est −$0.42 | — | −6.2% |
| May 8, 2025 | −$0.43 est −$0.42 | — | +0.4% |
| Mar 3, 2025 | −$0.42 est −$0.42 | — | −6.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Edgewise Therapeutics is $55.42, +20.7% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | H.C. Wainwright | $57 | +24.1% |
| Nov 6 | Wedbush | $51 | +11.0% |
| Nov 6 | Piper Sandler | $51 | +11.0% |
| Nov 5 | Stifel Nicolaus | $36 | −21.6% |
| Nov 5 | RBC Capital | $59 | +28.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Edgewise Therapeutics averaged −5.5% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 1 of 5 |
| Next 10 trading days | −4.0% | 1 of 5 |
| Next 15 trading days | −2.3% | 3 of 5 |
| Next 20 trading days | −5.5% | 2 of 5 |
| Next 30 trading days | +5.3% | 2 of 5 |
For scale, EWTX’s typical 20-trading-day move in either direction is about 10.7%.
Edgewise Therapeutics’s market cap is $4.94B, with a P/E ratio of 5.5 and revenue of $0 over the last twelve months.
Coverage of Edgewise Therapeutics this week reads neutral: 1 positive, 4 neutral and 0 negative headlines.
Edgewise Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Edgewise Therapeutics’s market cap is $4.94B at the Nov 13, 2026 close of $45.93, with 109.5M shares outstanding. The shares trade on a P/E ratio of 5.5.
The consensus analyst 12-month price target for Edgewise Therapeutics is $55.42, +20.7% from the last close. Of the 11 firms that rated the stock in the last 90 days, 9 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Edgewise Therapeutics is overvalued: the Nov 13, 2026 close of $45.93 is 6.1% above Gekko Fair Value of $43.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Edgewise Therapeutics is expected to report on Feb 25, 2027 (102 days away). Analysts expect earnings of −$0.43 per share on revenue of $9.62M. Edgewise Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 3.3% on average across the report.
Edgewise Therapeutics’s 52-week high is $48.78 and its 52-week low is $19.76; it closed at $45.93 on Nov 13, 2026, +117.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Edgewise Therapeutics over the last 30 days, with $1.11M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 6, 2026 with $1.11M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.